Latest news with #PEG
Yahoo
2 days ago
- Business
- Yahoo
What Are the 5 Best Bargain Artificial Intelligence (AI) Stocks to Buy Right Now?
Looking for low PEG ratios can be one way to find stocks that are currently on sale. AMD, Broadcom, and Nvidia are all cheap chip stocks given their projected growth. Salesforce and Adobe are two SaaS companies riding the AI wave that have fallen into the bargain bin. 10 stocks we like better than Nvidia › In a fast-growing segment like artificial intelligence (AI), it's not always easy to spot bargains; however, they can be found. One of the best ways to find bargains in a hot sector is to look beyond stocks' price-to-earnings (P/E) ratios and instead look at their price/earnings-to-growth (PEG) ratios, as this metric takes into consideration their earnings growth. Stocks with PEGs under 1 are generally considered undervalued, and based on this metric, five of the best values in the AI space are Advanced Micro Devices (NASDAQ: AMD), Broadcom (NASDAQ: AVGO), Salesforce (NYSE: CRM), Nvidia (NASDAQ: NVDA), and Adobe (NASDAQ: ADBE). Let's look at why these bargain AI stocks could be great buys. With a forward PEG of only 0.2 based on its projected 2026 growth, AMD is one of the cheapest stocks in the AI space -- if it can live up to its growth expectations. The company has already been seeing solid growth, with its overall revenue climbing by 36% last quarter to $7.44 billion, while its data center segment revenue surged 57% to $3.7 billion. The growth is being led by the company's strong positioning within server central processing units (CPUs) and solid growth from its graphics processing units (GPUs). The former acts as the brain for computers, while the latter provides the processing power. While the market for CPUs is not nearly as robust as the one for GPUs in the data center space, it is still a nice, growing market, and AMD has been taking share. However, the company's biggest opportunity will come when the AI market shifts from training more toward inference, which is expected to eventually be the much larger market. Inference is less technically demanding than training AI models, and things such as latency, power consumption, and cost come much more into play. This should allow AMD to take some market share in the GPU space, which would fuel a lot of growth moving forward. Broadcom is another cheap chip stock with a big opportunity in front of it. The company is seeing solid growth, with revenue jumping 25% last quarter to $14.9 billion, led by a 70% surge in its networking revenue. However, it is its foray into custom AI chips that has the potential to really drive growth higher. The company has seen strong success with its first custom AI chip customer, Alphabet, which has led to it winning additional customers. It sees its three furthest-along custom AI chip customers being a $60 billion to $90 billion serviceable market opportunity in its fiscal year 2027 (ending October 2027). If it can capture much of this opportunity, then the stock has a lot of potential upside from here. Notably, that number does not include more recent custom chip customer wins, including Apple. With a PEG of around 0.4 based on fiscal 2026 earnings, Broadcom has some serious upside potential. The biggest risk for it, as well as AMD, would be a slowdown in AI infrastructure spending. Given their recurring revenue model, software-as-as-service (SaaS) stocks typically trade at premium valuations, but that is not currently the case with Salesforce. With a forward PEG of around 0.5, the stock is in the bargain bin. However, the company has strong data-center and AI opportunities ahead. It's been seeing strong momentum with its Data Cloud solution, which helps customers unify their data into a single source, while it is also looking to be an agentic AI leader with its Agentforce platform. Last quarter, its Data Cloud annual recurring revenue (ARR) soared 120% year over year to more than $1 billion, while its Agentforce platform reached ARR of $100 million after only being launched last fall. The company is looking to tightly integrate Data Cloud and Agentforce with its apps, such as Tableau and Slack, to help spark a new era of digital labor. Meanwhile, it recently introduced a new flexible Agentforce consumption-based pricing model more aligned with outcomes to increase customer satisfaction and drive adoption. While there is always a risk its strategy will not work, at its current valuation, there is not much downside if it doesn't and a lot of upside if it does. It's sometimes hard to believe investors can get the preeminent AI growth stock at a forward PEG of only 0.7 times. However, based on fiscal 2026 projections, that's Nvidia's current valuation. The company has grown its data center revenue ninefold over the past two years, and more growth is ahead. While competitors are trying to make inroads, Nvidia is still the dominant market share leader when it comes to AI chips. It had an incredible 92% market share in the GPU space in Q1. Nvidia's secret sauce remains its CUDA software platform, which it developed to help expand the use of its chips beyond their original purpose of speeding up graphics rendering in video games. It has since layered a collection of libraries and tools on top of CUDA that enhance the performance of its chips in AI tasks. Nvidia's newest chips remain in high demand, and the company is well positioned to continue to be one of the biggest beneficiaries of the current AI data center buildout. An AI infrastructure spending slowdown is a risk, but the stock is far from being priced for perfection, giving it solid upside potential from here. Adobe isn't a high-growth stock, but with a PEG of 0.8, it's fallen into the category of growth at a reasonable price (GARP). While AI isn't helping accelerate revenue growth, it has helped it settle in a nice, high-single-digit, low-double-digit range. The company is using AI to help drive results within its creative software solutions, as well as its products aimed more toward business professionals. At the heart of its strategy is its Firefly generative AI model. Using just natural language prompts, FireFly can help users generate images, video, audio, and vector content that they can further manipulate with Adobe's creative tools, such as Photoshop, all while ensuring intellectual property protection. Document Cloud and Express have also incorporated FireFly into their platform and can handle everything from summarizing documents in Document Cloud to text-to-video generation in Express. All in all, the stock is inexpensive, and it looks like AI should continue to help power Adobe's results moving forward. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Geoffrey Seiler has positions in Alphabet and Salesforce. The Motley Fool has positions in and recommends Adobe, Advanced Micro Devices, Alphabet, Apple, Nvidia, and Salesforce. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. What Are the 5 Best Bargain Artificial Intelligence (AI) Stocks to Buy Right Now? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hindu
3 days ago
- Health
- The Hindu
Doctors successfully treat 32-year-old woman suffering from Spina Bifida
Doctors at Ankura Hospital, Hyderabad, performed a minimally invasive procedure on a 32-year-old woman suffering from Spina Bifida, a congenital condition that had caused severe bowel and bladder dysfunction since birth. The patient had previously undergone an Antegrade Continence Enema (ACE) surgery, which failed, leaving her reliant on manual enemas. Under the care of VVS Chandrasekharam and Parijat Ram Tripathi, a colonoscopic cecostomy technique was adopted. It involved placing a Percutaneous Endoscopic Gastrostomy (PEG) tube into the cecum using colonoscopic guidance, avoiding traditional surgery. Within 24 hours, a saline flush led to spontaneous stool passage, a first for the patient. She experienced no pain and was discharged the next day, said a release.
Yahoo
16-05-2025
- Business
- Yahoo
New FM station coming to Westfield
WESTFIELD — A new FM radio station is coming to Westfield. Westfield programming at WSKB is moving to WSFD-LP at 107.5 FM at the beginning of July. Westfield Media Specialist Peter Cowles said in late 2023, the Federal Communications Commission opened a one-month filing period for a low power FM station for the first time in a decade. Cowles received permission from Mayor Mike McCabe to apply as a public safety entity and jumped on it, he said. Westfield was one of two applicants out of eight that were selected. Cowles said Westfield had an original partnership with the Westfield State University student station WSKB, but the students at the university have been wanting it back. WSFD will be city-owned, with students at Westfield Technical Academy, where the studio is located, as the primary technicians on the station. He said it will also be open to the community at large for programming. The city is licensed with all three businesses, ASCAP, BMI and CESAC to play music. The station will also broadcast all emergency alerts in the city. On May 12, the Finance committee voted to recommend a transfer of $20,222 from the PEG Undesignated fiscal year 2025 account to the PEG Additional/Capital Equipment Account to purchase equipment for the station to finish off a 300 watt transmitter chain for the emergency Services alarm system. Cowles said they already have the computer, audio board and mics. Information Technology Manager Lenore Bernashe was able to get additional savings from Westfield Gas & Electric, who will increase the 80-foot tower located at the Water Department by adding 20 feet. Cowles said there are public safety receivers on it now that were put in six to seven years ago, and have a good range. Cowles said the 100-watt LPV station will reach Springfield and Northampton. 'That's why this site was perfect, and it's backed up on a mountain in Granby,' he said, adding that they will transition over on July 1 when the work is done. The new station is only one of the changes going on in the studio. On April 14, the City Council approved an expenditure of $296,915 from the PEG Undesignated Account, which is an enterprise fund, for a Mobile Sprinter Van. The van will cost $80,000 with $217,000 for customization and equipment including a 40-foot mast and camera, and will be used as a mobile television unit, able to cover city meetings and sporting events, and also able to be used as a short-term mobile command post as needed by the Police Department. Also in the works is a Chapter 74 certification for digital media, formerly called television and radio, as another career technical education program under graphic arts at WTA. 'I think it's a huge advantage for the program,' Cowles said. He said students will be able to run the radio programming and staff the vehicle, with a lot of opportunities to use the equipment and to train. He said they are presently rewriting the frameworks for the program. The school will be meeting with the Department of Elementary and Secondary Education in the next two weeks for the final word on Chapter 74, and have already toured the television station at WTA and made suggestions. Cowles said all in all they were impressed by the setup at the school. 'I can't believe what you did in such a small space — that's a quote from DESE,' he said. He said next year when the students return to school, the radio station WSFD will be up and running, and the mobile production unit will be on its way. 'A lot of changes happening all at once,' Cowles said. Read the original article on MassLive.
Yahoo
15-05-2025
- Business
- Yahoo
GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands the application of Optison to children of all ages, enabling clearer and more accurate echocardiogram imaging. As one of the only ultrasound agents in the United States without PEG, Optison offers a safer alternative for patients with PEG hypersensitivity. With a proven safety profile and decades of clinical use in adults, this FDA approval follows successful studies demonstrating Optison's efficacy in pediatric heart imaging. GE HealthCare's expanded pediatric indication reflects its commitment to advancing diagnostic tools that improve accuracy while addressing patient safety and comfort, positioning Optison as a vital solution in pediatric cardiology diagnostics. Shares of the company closed flat at $72.84 yesterday following the announcement. In the year-to-date period, GEHC shares have lost 6.9% against the industry's 5.5% growth. The S&P 500 decreased 0.6% in the same time frame. The FDA approval of Optison for pediatric use significantly broadens GEHC's market potential by enabling access to a new and critical patient segment. This expansion not only reinforces GEHC's leadership in ultrasound imaging agents but also drives incremental revenue growth through increased adoption in pediatric cardiology. The product is positioned to capture greater market share amid rising demand for advanced, non-invasive diagnostic tools. Over the long term, this approval strengthens GEHC's competitive edge, supports sustained earnings growth, and enhances investor confidence, making the stock poised for upward momentum. Meanwhile, GEHC currently has a market capitalization of $33.81 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Image Source: Zacks Investment Research Optison is an advanced ultrasound enhancing agent developed by GEHC, designed to improve the clarity and diagnostic accuracy of echocardiograms. By using gas-filled microbubbles that reflect ultrasound waves more effectively than surrounding tissues or blood, Optison enhances the visibility of the heart chambers and endocardial borders. This improved imaging capability is crucial for cardiologists to assess ventricular function and diagnose heart abnormalities or diseases accurately. Importantly, Optison is the only ultrasound enhancing agent available in the United States that does not contain PEG, a substance known to cause hypersensitivity or anaphylaxis in some patients, making it a safer option for individuals with PEG allergies. The recent FDA approval for Optison's pediatric indication marks a significant milestone for GEHC. Previously approved for adult use since 1997, Optison's pediatric approval follows a comprehensive Phase IV clinical study that demonstrated its efficacy and safety in children aged 9 to 17. This approval allows cardiologists to extend the use of Optison to pediatric patients with suboptimal echocardiograms, addressing the challenge of obtaining clear heart images in younger patients. The clinical study demonstrated that Optison enhanced the delineation of endocardial borders, improved visualization of left ventricular wall segments, and reduced the number of suboptimal echocardiogram images, thereby facilitating more accurate diagnoses and informed treatment decisions for pediatric heart conditions. Beyond its diagnostic benefits, Optison's unique safety profile adds considerable value in clinical settings. Unlike many other contrast agents, Optison's PEG-free formulation reduces the risk of hypersensitivity reactions, which is particularly important for vulnerable pediatric patients. Despite its proven safety over decades and use in over 5 million adult patients in the United States, serious adverse reactions remain rare but are closely monitored, with guidelines emphasizing the importance of patient assessment and the availability of resuscitation equipment during administration. The FDA approval of Optison for pediatric use is set to significantly strengthen GE HealthCare's Pharmaceutical Diagnostics (PDx) segment by expanding its addressable market and driving increased adoption of its ultrasound-enhancing agents. By enabling use in pediatric patients, an important and previously underserved group, Optison can capture new revenue streams and deepen GEHC's footprint in cardiac imaging diagnostics. This approval also enhances the segment's product portfolio with a PEG-free contrast agent, differentiating it from competitors and meeting growing demand for safer, more effective diagnostic tools. Ultimately, this milestone supports PDx's growth trajectory by boosting clinical adoption, improving patient outcomes, and reinforcing GE HealthCare's leadership in innovative diagnostic solutions. GEHC carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Indian Express
03-05-2025
- Health
- Indian Express
58-yr-old man breathes on his own after rare surgery at Pune hospital, six months on ventilator
Ruby Hall Clinic in Pune has achieved a medical breakthrough with the successful performance of phrenic nerve neuromodulation surgery, claimed to be the first in Maharashtra, on a patient with a breathing problem. This rare and complex procedure has enabled a 58-year-old man to breathe independently after being dependent on a mechanical ventilator for six months due to a spinal cord injury. This advanced surgical therapy stimulates the diaphragm, the major muscle required for breathing, and provides an essential solution for patients with neuromuscular weakness due to high cervical spinal cord injuries. The surgery was performed on Sanjay Pai under the expert care of the Intensivist Dr Kapil Zirpe, head of the Neuro Trauma Unit at Ruby Hall Clinic, and performed by Dr Manish Baldia, consultant functional neurosurgeon. Pai, who had suffered a high cervical spine injury (C3-C4 fracture) from a fall in his bathroom on July 25, 2024, was initially treated at another hospital. Despite undergoing C4 corpectomy, C3-C4 discectomy, and a range of spinal fusion surgeries, he remained quadriplegic and ventilator-dependent. Imaging studies confirmed a C3-C4 anterior subluxation and spinal cord compression, though no acute brain changes were observed. Pai was transferred to Ruby Hall Clinic on September 19, 2024, for further management, including neuro-monitoring, ventilator weaning support, and rehabilitation. He was conscious, oriented, on mechanical ventilation, and undergoing PEG (Percutaneous Endoscopic Gastrostomy) feeding and antibiotic therapy. Aware of the serious risks posed by prolonged ventilator use, including ventilator-associated pneumonia, stress ulcers, deep vein thrombosis, and pulmonary embolism, the medical team comprising Dr Richa Singh, Dr Manish Baldia, Dr Zirpe with his ICU team, and Dr Grant chose to perform the phrenic nerve neuromodulation surgery. Dr Baldia, who performed the surgery, said that initially, despite the efforts they were unable to wean him, but soon after phrenic nerve stimulation surgery, there was an improvement in his breathing. This was a highly delicate and rare procedure in which they placed a small device near the phrenic nerve. With the help of this device, the doctors were able to activate and control Pai's diaphragm externally through a remote and initiate the process of ventilator weaning. They programmed the stimulator as per the patient's physiological response, gradually enhancing diaphragm strength without inducing fatigue. 'The success of this surgery provides a new hope for patients with severe spinal cord injuries and long-term ventilator dependence,' Dr Purvez Grant, chief cardiologist, managing trustee and chairman of Ruby Hall Clinic, said at a media conference on April 30. Following the surgery, Pai showed excellent recovery. Gradually, his ventilator support was reduced, and by April 28, he was successfully shifted to the general ward for continued rehabilitation, the doctors said.
